Boston Scientific is back in the spotlight after Bank of America cut its price target on the medtech company to $68 from $105 on May 18, while keeping a Buy rating on the shares. The move came just weeks after Argus trimmed its target to $95 from $115 on April 27 and also reiterated a Buy.
The stock, which trades on the New York Stock Exchange under the ticker BSX, has become one of the most closely watched names in medical devices as analysts reassess what investors should pay for growth. Boston Scientific makes devices used in interventional medical procedures, with operations split between Cardiovascular and MedSurg. Its cardiovascular business includes cardiology and peripheral interventions, while MedSurg covers urology, endoscopy and neuromodulation.
BofA said it updated several price targets to reflect a new reality for medtech valuations after hosting 34 medtech companies in Las Vegas last week. The firm pointed to a year of few product cycles, inflation kicking up after the war, ACA pressures, utilization worries and even competition from data centers for healthcare capital. That backdrop led to a much lower target for Boston Scientific even as the firm kept its positive view on the shares.
Argus reached its own lower valuation call after Boston Scientific reported fiscal first-quarter results and cut guidance. In its April 27 update, the firm said the shares had recently underperformed the broader market, but argued the company remained well positioned in cardiovascular, electrophysiology and neuromodulation. It also said management had set more achievable objectives by lowering the outlook and that the price weakness created a buying opportunity.
The two notes together show how fast the tone has shifted around a company that is still being framed by some investors as one of the better medical stocks to own. The message from both firms was not that Boston Scientific has lost its place in the market. It is that the market has become less willing to pay up for it, even when the underlying franchise still earns a Buy.
That tension matters because Boston Scientific sits in a sector where valuation can move faster than operations. A strong product story is no longer enough to preserve a premium if analysts think the broader medtech backdrop is resetting. For BSX stock, the immediate question is not whether the company still has growth engines, but how much investors are now willing to pay for them.
